Dengue Treatment in India: Clinical Management Guide

This dengue India reference is written for a treating physician or hospital administrator, not as a self-treatment guide. It covers the phase-based clinical framework, the warning-sign triage that decides admission, the platelet question that drives most avoidable transfusions, and where drug and diagnostic-kit availability inside a hospital pharmacy actually matters.

What are the three clinical phases of dengue?

Every dengue case moves through a febrile phase (days 1 to 3), a critical phase (days 3 to 7, often starting as fever breaks), and a recovery phase. The critical phase is where plasma leakage, bleeding and shock happen, and where most preventable deaths occur from either too little or too much IV fluid.

The febrile phase looks like any acute viral illness: high fever, headache, retro-orbital pain, myalgia, and a positive NS1 antigen test from day one. The danger is that clinicians and patients both relax exactly when the fever breaks, which is precisely when the critical phase often begins. The NVBDCP 2023 clinical management guideline frames this defervescence window as the highest-risk 24–48 hours of the entire illness.

How is dengue actually diagnosed in an Indian hospital?

NVBDCP recommends NS1 antigen ELISA for days 1–5 of illness and IgM capture ELISA (MAC-ELISA) from day 5 onward, run through the government's apex referral laboratory network. Rapid card-test kits are explicitly flagged as unreliable for confirmatory diagnosis due to high false-positive rates.

A hospital lab that only stocks rapid cassette kits, common in smaller Tier 2/3 nursing homes, is working outside the government-recommended diagnostic pathway. The NCVBDC dengue case-management page lists the government-designated sentinel and apex referral labs by state for confirmatory ELISA testing.

What does the WHO severity classification actually change in management?

WHO's 2009 classification splits cases into dengue without warning signs, dengue with warning signs, and severe dengue. The category, not the fever curve alone, decides whether a patient is managed as an outpatient, admitted for observation, or moved to an ICU-capable facility.

Warning signs per the WHO dengue guidelines include abdominal pain or tenderness, persistent vomiting, clinical fluid accumulation (ascites, pleural effusion), mucosal bleeding, lethargy or restlessness, liver enlargement beyond 2 cm, and a rising hematocrit alongside a rapid platelet drop. Any one of these in a patient whose fever is falling is an admission criterion, not a discharge criterion.

What is the actual platelet transfusion threshold?

Prophylactic platelet transfusion in a patient who is not bleeding is not indicated even at very low counts. Most current guidance reserves transfusion for active clinically significant bleeding, or for counts below roughly 10,000 to 20,000/mm³ with other risk factors present, not as a routine response to any low number. This is one of the most over-treated aspects of dengue management in private-sector India.

Indian randomised-trial data and subsequent WHO-aligned guidance both found no mortality or bleeding benefit from prophylactic transfusion at platelet counts of 10,000 to 20,000/mm³ in stable, non-bleeding patients. Retrospective audits of private hospitals in India have repeatedly found transfusion rates far above what guidelines support, largely driven by family anxiety over a falling number rather than a clinical indication. The PMC-hosted Indian cohort study on dengue laboratory correlates documents how viral load, NS1 positivity and platelet trajectory correlate with actual outcome, a more useful predictor than the platelet count in isolation.

What fluid management does the guideline actually specify?

Isotonic crystalloid (normal saline or Ringer's lactate) is the first-line fluid in the critical phase, titrated to urine output, hematocrit trend and vital signs rather than given at a fixed rate. Over-resuscitation causes the fluid-overload complications, pleural effusion and pulmonary edema, that kill patients who were never in true shock.

NVBDCP's clinical protocol specifies stepwise fluid-rate adjustment based on hourly reassessment during the critical 24 to 48 hour window, with colloid reserved for cases not responding to crystalloid alone. This is a monitoring-intensive protocol that assumes nursing capacity for hourly vitals and serial hematocrit, a real constraint in Tier 2/3 nursing homes without a dedicated dengue ward, per the NVBDCP guideline document.

What medicines are actually used, and which are contraindicated?

Paracetamol is the only routinely recommended antipyretic. NSAIDs (ibuprofen, diclofenac, mefenamic acid) and aspirin are contraindicated throughout the illness because of the bleeding risk and gastric irritation on top of dengue's own platelet and coagulation effects. This is one of the most consistently repeated warnings across NVBDCP and WHO material on dengue India management.

There is no antiviral drug approved for dengue in India; supportive care is the entire pharmacological picture beyond antipyretics and, where indicated, IV fluids and blood products. Any hospital pharmacy claiming a dengue "cure" medicine is outside guideline-based practice. The WHO dengue fact sheet states this plainly: management is supportive, and early recognition of warning signs is what actually reduces mortality, not a drug.

Is a dengue vaccine available in India?

Not yet at meaningful scale. Qdenga (TAK-003), the tetravalent dengue vaccine, has regulatory approval in a number of countries but is not part of India's national immunisation programme, and hospitals should not represent it as routinely available or CDSCO-cleared for general use without checking current status directly with CDSCO before advising a patient either way.

Why does hospital-level stocking of dengue supportive care actually matter?

None of this protocol works if the pharmacy can't reliably supply what the critical phase needs that day: IV crystalloids in volume, safe antipyretic formulations, and same-day access to platelet units through a blood bank tie-up. A stockout at 2 a.m. in peak season sends the family to an outside chemist, or a different facility.

That's a continuity-of-care failure as much as a revenue one. A patient who leaves for an outside pharmacy mid-admission often doesn't come back for follow-up bloodwork at the same facility. Our managed hospital pharmacy services piece covers how in-house stocking reliability is built through dengue season surges, and our prescription leakage piece covers what a single walked-out prescription costs a hospital beyond the immediate sale. During dengue India outbreak peaks, this stocking reliability is what keeps admissions inside the hospital's own pharmacy loop, per the state vector-borne surveillance data NVBDCP publishes each season.

Sources

1. 1National Guidelines for Clinical Management of Dengue Fever 2023 — National Centre for Vector Borne Diseases Control, MoHFW
2. 2Guidelines for Clinical Management of DF/DHF/DSS — NCVBDC, MoHFW
3. 3Dengue and severe dengue fact sheet — World Health Organization
4. 4Management of dengue case — NCVBDC, MoHFW
5. 5Association of viral load, NS1 antigen and laboratory parameters with dengue outcome — PMC, National Institutes of Health
6. 6Central Drugs Standard Control Organisation — drug and vaccine approval status, Government of India

This article is for informational purposes for clinicians and hospital administrators and is not a substitute for professional medical advice or current clinical guidelines. Treatment decisions must follow current NVBDCP/WHO protocols and individual patient assessment by a qualified physician.